Added to YB: 2024-09-24
Pitch date: 2024-06-30
SRPT [bullish]
Sarepta Therapeutics, Inc.
-85.88%
current return
Author Info
No bio for this author
Company Info
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Market Cap
$2.0B
Pitch Price
$158.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
25.37
P/E
-6.79
EV/Sales
0.99
Sector
Biotechnology
Category
growth
Janus Henderson Global Life Sciences Diversified ADR Managed Account Portfolio Holding: Sarepta Therapeutics, Inc.
SRPT: DMD leader Sarepta's gene therapy Elevidys expanded FDA approval to all 4+ patients, up from 4-5 year walkers. High unmet need for severe muscular dystrophy. Expect rapid sales acceleration for breakthrough treatment. Long-term holding, top contributor for 2 quarters.
Read full article (1 min)